Abstracts of the 22 nd National Congress of Digestive Diseases / Digestive and Liver Disease 48S2 (2016) e67–e231 e195 Table 2 Left-sided Extensive/ Proctitis Proctosigmoiditis colitis Pancolitis Disease activity Remission 7 (29%) 21 (47%) 13 (65%) 20 (43%) Mild 12 (50%) 22 (49%) 5 (25%) 17 (37%) Moderate 4 (16%) 1 (2%) 1 (5%) 7 (15%) Severe 1 (5%) 1 (2%) 1 (5%) 2 (5%) Therapy Oral 7 (30%) 24 (53%) 17 (85%) 35 (76%) Topical 3 (12%) 3 (7%) 0 0 Combined 12 (50%) 16 (35%) 2 (10%) 10 (22%) Other* 3 (12%) 15 (33%) 1 (5%) 21 (46%) No therapy 2 (8%) 2 (8%) 1 (5%) 1(2%) * Other therapies: Steroids, Immunosoppressors or anti-TNF antibodies Conclusions: Topical therapy is underused in our coohort of patients, especially in patients with pancolitis. A dedicated IBD outpatients unit may help to ameliorate the rate of adherence to medical topical treatment. Further studies are needed to evaluate factors affecting adherence and possibile strategies to improve topical therapy use. P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS Magarotto A.* 1 , Shepherd T. 2 , Balendran P. 3 , Goodhand J. 3 , Cronin E. 4 , Graveson K. 2 , Wood E. 3 , Marelli L. 3 , Hamilton M. 2 , Conte D. 1 , Caprioli F. 1 , Murray C. 2 1 IRCCS Ospedale Cà Granda Policlinico di Milano, Milan, Italy, 2 Gastroenterology Department, Royal Free Hospital, London, United Kingdom, 3 Gastroenterology Department, Homerton Hospital, London, United Kingdom, 4 United Kingdom Background and aim: Iron deficiency anemia (IDA) represents a frequent and undertreated finding in IBD patients. Oral iron supplementation is considered as effective as intravenous iron for treating IBD-associated IDA, even if active intestinal inflammation may limit iron enteral absorption. However, response to oral iron supplementation in IBD with respect to inflammatory status is still largely unknown. Present retrospective study was aimed at determining whether the effectiveness of antiTNF therapy is associated with response to iron supplementation in IBD-related IDA. Material and methods: Patient series included 174 IBD patients with IBD-related IDA, examined at the enrollement and after long term antiTNF regimen given at a single UK center (Royal Free Hospital, London). Primary response was defined as the combination at least two of the following: absence of symptoms, steroid withdrawal, and C reactive protein normalization. Primary non-response was defined as one or none of the above. Results: In the present cohort, 155/174 patients (89%) had Crohn’s disease and 85/174 (49%) were anaemic at anti-TNF initiation, with a mean [SEM] haemoglobin level of 10.89[0.144] g/dl. At baseline, 51/85 (60%) had iron deficiency anaemia, 15/85 (18%) anaemia of chronic disease, 4/85 (5%) vitamin B12/folate deficiency and 15/85 (17%) undefined. Overall, 35 out of the 51 IDA patients (69%) were treated with oral iron. In this set of patients with iron supplementation (28 with CD and 7 with UC), there was no difference in baseline mean haemoglobin levels in responders as compared with nonresponders to antiTNF treatment (11.04[0.158] vs 10.59[0.282]), p=0.14. Notably, responders had a slightly greater increase in haemoglobin levels at 14 weeks (11.04 to 12.05 vs. 10.59 to 11.16 in non-responders) even if no significant difference in mean change in haemoglobin was observed (responders +1.01[0.179]; non-responders +0.60[0.299]), p=0.21. Conclusions: Our data suggest that oral iron supplementation is effective in increasing haemoglobin levels in IBD patients, regardless to their response to anti-TNF therapy which does not impair oral iron absorption and could be used at the same time. These results suggest that oral iron should be considered in all IBD patients with active inflammation. P.14.4 ESCHERICHIA COLI NISSLE 1917 IN ULCERATIVE COLITIS TREATMENT: SYSTEMATIC REVIEW AND META-ANALYSIS Principi M., Losurdo G.*, Iannone A., Contaldo A., Ierardi E., Di Leo A. UO Gastroenterologia universitaria, Policlinico di Bari, Bari, Italy Background and aim: Escherichia coli Nissle 1917 (EcN) has been advised as a therapeutic tool for Ulcerative Colitis (UC) treatment. However, to date, no meta-analysis has been performed on the topic. Material and methods: We performed a literature search on PubMed, MEDLINE, Science Direct and EMBASE. We evaluated success rates for induction of remission, relapse rates and side effects, expressed as Intention-To-Treat. Odd ratios (OR), pooled OR and 95% confidence intervals (CI) were calculated, based on the Mantel-Haenszel method. Heterogeneity was assessed by using the c2 and I2 statistics and, if present, a random-effects model was adopted. Results: We selected six eligible trials, with 719 patients, 390 assigned to the study group and 329 to the control group. EcN induced remission in 61.6% of cases, while in the control group (mesalazine) the remission was achieved in 69.5% of cases, with a mean difference of 7.9%. The pooled OR was 0.92 (95% CI 0.15-9.66, p=0.93). A single study showed a better performance of EcN than placebo. A relapse of the disease occurred in 36.8% in EcN group and in 36.1% in control group (mesalazine), with a mean difference of 0.8%, OR=1.07, with a 95% CI of 0.70-1.64 (p=0.74). Side effects were comparable (OR=1.44, 95% CI 0.80-2.59, p=0.22). Conclusions: EcN is equivalent to mesalazine in preventing disease relapse, thus confirming current guidelines recommendations. EcN seems to be as effective as controls in inducing the remission; therefore, its use cannot be recommended as in one study the comparison was performed against placebo despite further studies may be helpful for this topic. P.14.5 METASTATIC CUTANEOUS CROHN’S DISEASE OF THE FACE TREATED WITH INFLIXIMAB: CASE REPORT AND FOLLOW UP Peruzzi E.* 1 , Piersimoni F. 1 , Carella A. 1 , Giacchetti A. 1 , Ricotti G. 1 , Giangiacomi M. 2 1 INRCA, Ancona, Italy, 2 Azienda OSP Riuniti, ANCONA, Italy Background and aim: MCD is a rare extraintestinal manifestation of active CD. Only a few cases of facial involvement have been reported. Diagnosis can be difficult and treatmenet is largely anedoctal. Sometime improvement has been reported with drugs used for CD. We describe a patient with intestinal CD disease in remission but active MCD refractory to usually drugs used for CD, that improved after infliximab (IFX). Material and methods: In 2008 a 58-y-old female was refferred to Dermatology Department for evaluation of painful erithematous purple papulas, nodules and plaques on her face, she referred in 2006 a ileocecal resection for stenosing and fistulizing CD and since then in clinical and endoscopi remission. Empiric treatment with topical and sistemic antibiotics and steroids and azathioprine was ineffective, cutaneous biopsy was performed; histologic examination